Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 4/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27729887 | 0.88 | MEN1 (0.46) | RAB9AGAAHDAC3HDAC1HDAC2 | |
| SCHEMBL14935007 | 0.81 | HDAC3 (0.68) | RAB9AGAAHDAC3HDAC1HDAC2 | |
| SCHEMBL12894269 | 0.78 | HDAC3 (0.52) | RAB9AGAAHDAC3HDAC1HDAC2 | |
| SCHEMBL6835468 | 0.77 | GAA (0.61) | RAB9AGAAHDAC3HDAC1HDAC2 | |
| SCHEMBL1041427 | 0.77 | RAB9A (0.49) | RAB9AGAAHDAC3HDAC1HDAC2 | |
| Hydrochloric Acid SCHEMBL9313818 | 0.76 | GAA (0.60) | RAB9AGAAHDAC3HDAC1HDAC2 | |
| SCHEMBL5068529 | 0.73 | KAT2B (0.56) | HDAC6 | |
| SCHEMBL4508909 | 0.71 | HDAC3 (0.50) | RAB9AGAAHDAC3HDAC1HDAC2 | |
| SCHEMBL6660579 | 0.71 | POLB (0.68) | RAB9AHDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL14679379 | 0.70 | HDAC3 (0.69) | RAB9AHDAC3HDAC1HDAC2HDAC10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090028858-A1 | SUBSTITUTED QUINOLINE DERIVATIVES | NOVARTIS VACCINES AND DIAGNOTICS, INC. | 2009-01-29 | — | — | US | claimed |
| US-7452996-B2 | Substituted quinoline derivatives | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-11-18 | — | — | US | claimed |
| EP-1753723-B1 | SUBSTITUTED QUINOLINE DERIVATIVES AS MITOTIC KINESIN INHIBITORS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-08-13 | — | — | EP | claimed |
| CN-101233115-A | Indole and benzimidazole derivatives | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-07-30 | — | — | CN | claimed |
| EP-1753723-A1 | SUBSTITUTED QUINOLINE DERIVATIVES AS MITOTIC KINESIN INHIBITORS | Novartis Vaccines and Diagnostics, Inc. (US) | 2007-02-21 | — | — | EP | claimed |
| WO-2005113507-A1 | SUBSTITUTED QUINOLINE DERIVATIVES AS MITOTIC KINESIN INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2005-12-01 | — | — | WO | claimed |
| US-20050261337-A1 | N-(3-aminopropyl)-N- [1-(3-benzylquinolin-2-yl)- 2-methylpropyl]-3-fluoro-4-methylbenzamide; cancer; disorder mediated, at least in part by kinesin-related proteins | WANG WEIBO | 2005-11-24 | — | — | US | claimed |
| US-20090028858-A1 | SUBSTITUTED QUINOLINE DERIVATIVES | NOVARTIS VACCINES AND DIAGNOTICS, INC. | 2009-01-29 | — | — | US | disclosed |
| US-7452996-B2 | Substituted quinoline derivatives | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| EP-1753723-B1 | SUBSTITUTED QUINOLINE DERIVATIVES AS MITOTIC KINESIN INHIBITORS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-08-13 | — | — | EP | disclosed |
| CN-101233115-A | Indole and benzimidazole derivatives | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-07-30 | — | — | CN | disclosed |
| EP-1753723-A1 | SUBSTITUTED QUINOLINE DERIVATIVES AS MITOTIC KINESIN INHIBITORS | Novartis Vaccines and Diagnostics, Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005113507-A1 | SUBSTITUTED QUINOLINE DERIVATIVES AS MITOTIC KINESIN INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2005-12-01 | — | — | WO | disclosed |
| US-20050261337-A1 | N-(3-aminopropyl)-N- [1-(3-benzylquinolin-2-yl)- 2-methylpropyl]-3-fluoro-4-methylbenzamide; cancer; disorder mediated, at least in part by kinesin-related proteins | WANG WEIBO | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090028858-A1 | SUBSTITUTED QUINOLINE DERIVATIVES | ABCG2, ABCB1, UGT2B7 | RAB9A 500/4885GAA 346/4885HDAC3 322/4885 |
| US-20050261337-A1 | N-(3-aminopropyl)-N- [1-(3-benzylquinolin-2-yl)- 2-methylpropyl]-3-fluoro-4-methylbenzamide; cancer; disorder mediated, at least in part by kinesin-related proteins | KIF5B, KIF2C, KIF5C | RAB9A 205/4885GAA 1626/4885HDAC3 1122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.